FDA Approves Gedatolisib with Fulvestrant, With or Without Palbociclib, for HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer By Ogkologos - September 9, 2026 54 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Study 1 of the VIKTORIA-1 Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Relacorilant Annual Multicancer Early Detection Test Not Associated with a Lower Incidence Rate of Stage III or IV Cancer After Three Screening Rounds and 12... European Parliament Report on Europe’s Beating Cancer Plan Strengthens Commitment to Rare Cancer Care MOST POPULAR FDA Approvals Expand Initial Treatment Options for Multiple Myeloma January 7, 2025 Sublobar Resection Noninferior to Lobectomy in Terms of DFS Among Patients... February 17, 2023 Screening People at High Risk for Pancreatic Cancer May Help Them... August 2, 2024 Tips On Staying Cool During a Heat Wave June 30, 2021 Load more HOT NEWS Coping With Advanced Melanoma and a Second Cancer Diagnosis: A Survivor’s... Intracranial Efficacy of Pembrolizumab in Patients with Brain Metastases Nurse With Terminal Breast Cancer Spends Her Days Caring For Pediatric... The First Report from the Cancer Programme of the 100,000 Genomes...
